Fitxers

861421.pdf (645.42 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2024-03-27

Llicència de publicació

cc-by-nc (c) Gallego Ana et al., 2024
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/215970

Study protocol for a three-arm randomized controlled trial investigating the effectiveness cost-utility and physiological effects of a fully self-guided digital Acceptance and Commitment Therapy for Spanish patients with fibromyalgia

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1177/20552076241239177

Resum

Objective:Fibromyalgia (FM) is a prevalent pain syndrome with significant healthcare and societal costs. The aim of the SMART-FM-SP study is to determine the effectiveness, cost-utility, and physiological effects in patients with FM of a digital intervention (STANZA®) currently marketed in the United States, which delivers smartphone-based, fully self-guided Acceptance and Commitment Therapy (Digital ACT) for treating FM-related symptoms. Methods:A single-site, parallel-group, superiority, randomized controlled trial (RCT) will be conducted, including a total of 360 adults diagnosed with FM. Individuals will be randomly allocated (1:1:1) to treatment as usual (TAU), to TAU plus 12 weeks of treatment with Digital ACT, or to TAU plus 12 weeks of treatment with digital symptom tracking (i.e. FibroST). Participants will be assessed at baseline, post-treatment, and 6-month follow-up. An intention-to-treat analysis using linear mixed models will be computed to analyze the effects of Digital ACT on functional impairment (primary outcome), as measured by the Fibromyalgia Impact Questionnaire Revised at 6 months from the inception of the treatment. Secondary outcomes include impression of change, symptoms of distress, pain catastrophising, quality of life, cost-utility, and selected biomarkers (cortisol and cortisone, immune-inflammatory markers, and FKBP5 gene polymorphisms). The role of ACT-related processes of change will be tested with path analyses. Conclusions:This study is the first RCT that tests Digital ACT for Spanish patients with FM. Results will be important not only for patients and clinicians, but also for policy makers by examining the cost-utility of the app in a public healthcare context.

Matèries

Fibromiàlgia, Teràpia d'acceptació i compromís, Aplicacions mòbils, Telèfons intel·ligents, Dolor crònic

Matèries (anglès)

Fibromyalgia, Acceptance and commitment therapy, Mobile apps, Smartphones, Chronic pain

Citació

Col·leccions

Articles publicats en revistes (Biologia Evolutiva, Ecologia i Ciències Ambientals)

Citació

GALLEGO, Ana, et al. Study protocol for a three-arm randomized controlled trial investigating the effectiveness cost-utility and physiological effects of a fully self-guided digital Acceptance and Commitment Therapy for Spanish patients with fibromyalgia. Digital Health. 2024. Vol. 10, num. 1-12. ISSN 2055-2076. [consulted: 22 of May of 2026]. Available at: https://hdl.handle.net/2445/215970

Exportar metadades

JSON - METS

Compartir registre